ArticleJournal of substance abuse treatment2022
Use of long-acting injectable buprenorphine in the correctional setting.
Article in Journal of substance abuse treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Best practice guidelines for viral hepatitis service delivery in prisons.The Lancet. Infectious diseases · 2026Pooled it
- Extended-release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review.Addiction (Abingdon, England) · 2025Pooled it
- Experiences of People Who Discontinue Long-Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia.Drug and alcohol review · 2026Article
- Initiation, retention, and discontinuation of extended-release buprenorphine (BUP-XR) for opioid dependence: A single-arm multi-site trial in Ukraine.The International journal on drug policy · 2026Article
- Perceived impacts of medications for opioid use disorder implementation on mental health services and substance use counseling in carceral settings: qualitative findings from 13 Massachusetts jails.Addiction science & clinical practice · 2025Article
- Implementation of harm reduction strategies in criminal-legal systems: a scoping review of the literature.Health & justice · 2025Review
- Injectable buprenorphine during transition out of prison: A pilot partially randomized preference trial protocol.Contemporary clinical trials · 2025Article
- State-Mandated Opioid Use Disorder Treatment In Maryland Jails Helped Patients Recover Despite Gaps In Care.Health affairs (Project Hope) · 2025Article
- Medication for opioid use disorder service delivery in carceral facilities: update and summary report.Health & justice · 2025Review
- Patient Satisfaction and Resource Utilization Following Introduction of Long-Acting Injectable Buprenorphine (LAIB) in Scottish Prisons.Substance abuse and rehabilitation · 2025Article
- Initiation and Dosing of Extended-Release Buprenorphine: A Narrative Review of Emerging Approaches for Patients Who Use Fentanyl.Substance abuse and rehabilitation · 2025Review
- Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study.Addiction science & clinical practice · 2024Article
- Community buprenorphine continuation post-release following extended release vs. sublingual buprenorphine during incarceration: a pilot project in Maine.Health & justice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAs overdoses due to opioids rise, medications for opioid use disorder (MOUD) continue to be underemployed, resulting in limited access to potentially life-saving treatment. Substance use disorders are prevalent in individuals who are incarcerated, and these individuals are at increased risk for death postrelease due to overdose. Few jails and prisons offer MOUD and most limit access. Extended-release buprenorphine (XR-BUP), a novel monthly injectable MOUD formulation, could be uniquely poised to address treatment access in correctional settings.
methodsThis study linked a retrospective cohort design of statewide datasets to evaluate the real-world use of XR-BUP. The study included individuals (N = 54) who received XR-BUP while incarcerated from January 2019 through February 2022. The study was conducted at the Rhode Island Department of Corrections, with the nation's first comprehensive statewide correctional MOUD program.
resultsFifty-four individuals received a combined total of 162 injections during the study period. The study found no evidence of tampering with the injection site, indicating no attempts by participants to remove, hoard, or divert the medication. Sixty-one percent reported at least one adverse effect after injections were received, with an average of 2.8 side effects. Sixty-one percent of those released on XR-BUP engaged in MOUD after release, 30 % continued with XR-BUP.
conclusionsXR-BUP is feasible and acceptable in correctional settings. XR-BUP addresses administrative concerns of diversion that obstruct lifesaving MOUD and offers another safe and effective treatment option. Further studies and trials should continue to assess this novel medication's ability to treat opioid addiction in the correctional setting and upon release to the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.